NovoCure Ltd (NVCR) has released an update to notify the public and investors about a regulation fd disclosure.
NovoCure Limited announced on January 18, 2024, that the FDA has accepted its Premarket Approval application for the use of Tumor Treating Fields therapy in conjunction with standard treatments for non-small cell lung cancer after the failure of platinum-based therapy. The press release detailing this acceptance is included with the announcement, and the information is not considered “filed” under specific securities regulations unless explicitly referenced in a filing.
For further insights into NVCR stock, check out TipRanks’ Stock Analysis page.
